Success Metrics

Clinical Success Rate
92.3%

Based on 24 completed trials

Completion Rate
92%(24/26)
Active Trials
3(9%)
Results Posted
71%(17 trials)
Terminated
2(6%)

Phase Distribution

Ph phase_2
15
47%
Ph phase_1
11
34%
Ph phase_3
4
13%
Ph not_applicable
1
3%

Phase Distribution

11

Early Stage

15

Mid Stage

4

Late Stage

Phase Distribution31 total trials
Phase 1Safety & dosage
11(35.5%)
Phase 2Efficacy & side effects
15(48.4%)
Phase 3Large-scale testing
4(12.9%)
N/ANon-phased studies
1(3.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

92.3%

24 of 26 finished

Non-Completion Rate

7.7%

2 ended early

Currently Active

3

trials recruiting

Total Trials

32

all time

Status Distribution
Active(3)
Completed(24)
Terminated(2)
Other(3)

Detailed Status

Completed24
unknown3
Recruiting2
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
32
Active
3
Success Rate
92.3%
Most Advanced
Phase 3

Trials by Phase

Phase 111 (35.5%)
Phase 215 (48.4%)
Phase 34 (12.9%)
N/A1 (3.2%)

Trials by Status

unknown39%
recruiting26%
active_not_recruiting13%
completed2475%
terminated26%

Recent Activity

3 active trials
Showing 5 of 32
recruitingphase_2

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

NCT05748834
recruitingphase_1

Combination Therapy for Recurrent Ovarian Cancer

NCT05610735
completedphase_2

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903
active_not_recruiting

Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

NCT04055753
completedphase_2

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

NCT00608972
View all 32 trials

Clinical Trials (32)

Showing 20 of 32 trialsScroll for more
NCT05748834Phase 2

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Recruiting
NCT05610735Phase 1

Combination Therapy for Recurrent Ovarian Cancer

Recruiting
NCT02489903Phase 2

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed
NCT04055753

Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma

Active Not Recruiting
NCT00608972Phase 2

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

Completed
NCT01035658Phase 1

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Terminated
NCT01736943Phase 2

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

Completed
NCT00442260Phase 1

Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer

Completed
NCT00290433Phase 2

Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Completed
NCT01902225Phase 1

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

Completed
NCT00456989Phase 1

Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer

Completed
NCT00846612Phase 1

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Completed
NCT00761644Phase 1

Doxil, Bevacizumab and Temsirolimus Trial

Completed
NCT01846611Phase 3

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed
NCT00307294Phase 2

Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)

Completed
NCT00222105Phase 2

A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life

Completed
NCT00724568Phase 1

Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Completed
NCT00097981Phase 3

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

Completed
NCT00630409Phase 2

Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma

Completed
NCT00945139Phase 2

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
32